Baseline Patient Forms

Similar documents
EFFECTS OF NICOTINAMIDE AND LANTHANUM CARBONATE ON SERUM PHOSPHATE AND FGF23 LEVELS IN PATIENTS WITH STAGE 3-4 CHRONIC KIDNEY DISEASE

BASE 24-HOUR URINE COLLECTION LITHOLINK CORE LAB

Revision of 11/15/2017 Form # 249 Page 1 of 7 Pilot Clinical Trials in CKD Follow-Up Pill Dispensing and Counting Form # COMBINE

ARCADIA Study Coordinator Training Investigator Meeting

Research Compliance and Quality Assurance Program (RCQA): Audit Checklist Subject Specific

Bicarbonate Administration to Stabilize egfr. (BASE Study)

A Guide to Your Visits for the FAiRE LGS Study

Closeout of the HALT Polycystic Kidney Disease Treatment Network Trials

Goal of site data management 12/2/2009. Ultimate goal: reliable and valid clinical trial to improve health

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

November 9, Clarification Memo 1 Version 3.0 HVTN 704/HPTN 085

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.

8.0 ADVERSE EVENT HANDLING

Consent and Authorization Document

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Study Design and Materials

The REDOXS Study. REducing Deaths due to OXidative Stress. A randomized trial of glutamine and antioxidant supplementation in critically ill patients

Recruitment and Consenting

Study Protocol Outline (Vitamin D and Autism Pilot Study)

Location of initiative York Region Chronic Kidney Disease Program, Mackenzie Richmond Hill Hospital, Richmond Hill, ON

SYNOPSIS. Clinical Study Report IM Double-blind Period

2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome

Maryland Vaccines for Children Program VACCINE MANAGEMENT PLAN

ClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT)

Secondary Hyperparathyroidism: Where are we now?

The REDOXS Study. REducing Deaths due to OXidative Stress. A randomized trial of glutamine and antioxidant supplementation in critically ill patients

What is Quitline Iowa?

MAPS Study MP-10 1 Study Synopsis UK April 18, 2011

GSK , 2.0, 18, 2014, DAIDS

Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome

Getting to the core of customer satisfaction in skilled nursing and assisted living. Satisfaction Questionnaire & User s Manual

Asthma Please complete packet and return to nurse at child s school

PVDOMICS: ECG Training Module

ACCREDITATION APPLICATION FOR COUNCIL ON RENAL NUTRITION ACTIVITIES

Inspections, Compliance, Enforcement, and Criminal Investigations

Northwestern University. Consent Form and HIPAA Authorization for Research

SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity

Individual Study Table Referring to Part of Dossier: Volume: Page:

2018 ASIAN PACIFIC CONGRESS OF NEPHROLOGY

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.

Background and Significance To be completed by the project s Principal Investigator (PI) and should include rationale for the selected study design.

SYNOPSIS. Issue Date: 25 Oct 2011

DEMOGRAPHICS PHYSICAL ATTRIBUTES VITAL SIGNS. Protocol: ABC-123 SCREENING. Subject ID. Subject Initials. Visit Date: / / [ YYYY/MM/DD]

Access to Experimental Therapies / FDA Expanded Access Programs

RITAZAREM. CRF Completion Guidelines

Strategic Peer-Enhanced Care and Treatment Retention Model (SPECTRuM) Initiative. Intervention Protocol #2

CaseBuilder - Quick Reference Guide

Demystifiying Subject Withdrawl Jane Liesveld, MD Dept. of Medicine; JPWCI

Standard Operating Procedure 11. Completion of DAFNE Data Collection: Full Post Course Form F04.010, Version 8

Measure #167 (NQF 0114): Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure National Quality Strategy Domain: Effective Clinical Care

What to Expect When You Visit. The First Visit. Follow Up Visits. Laboratory Tests

Parisa Mirzadehgan, MPH, CCRP

MAPS Study MT1 CRF Page 1. Baseline Evaluations: Record clinically significant findings on the Medical History CRF

15.0 CONTROL OF STUDY DRUG

MTN 003 MONTHS 1 & 2 VISIT PRESENTATION ZIMBABWE TEAM JULIET MOYO RESEARCH NURSE MARTHA MASAWI COUNSELLOR

SYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.

PROFICIENCY TESTING POLICY

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy

Julie Nelson RNC/WHNP-BC Epidemiology NURS 6313

Alliance A Symptomatic brain radionecrosis after receiving radiosurgery for

COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION - Medications POLICY NUMBER: 510

Systolic Blood Pressure Intervention Trial (SPRINT)

Study Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)

Part I. Prior Authorization Criteria and Policy

IMPAACT MOCHA More Options for Children and Adolescents

Protocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.

Kentucky Peer Support Specialist Training Registration and Application Procedures

Assessing Mothers Knowledge of the Wisconsin Newborn Screening Program. Sara Wolfgram UW Master of Public Health Symposium August 11, 2006

If the HPTN 082 protocol is amended in the future, this Letter of Amendment will be incorporated into the next version.

Tomorrow s SMILES Program

WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS

Informatics Core. Arthur Toga May 2014

Study Center(s): The study was conducted at 39 study sites in Japan.

Veterans Certified Peer Specialist Training

Pre-exposure Prophylaxis for HIV Prevention

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

UARTERLY ENTAL. Welcome to the New Dental Newsletter ACS FIELD REPRESENTATIVE VISITS

Certified Peer Specialist Training Application

UC Brain Tumor Center Molecular Therapeutics Pilot Grant Program 2013/2014

Synopsis (C0168T37 ACT 1)

TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:

HOSPICE INFORMATION FOR MEDICARE PART D PLANS

Center for Family Health Policy

UW MEDICINE PATIENT EDUCATION. Discharge Checklist. After a kidney/pancreas transplant. When can I leave the hospital?

Randomized Controlled Trial

Quality of Life of HIV-infected Patients Study

2. Chapter 2: Eligibility

Annex. Scientific conclusions and grounds for refusal presented by the European Medicines Agency

SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines

NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN

The Johns Hopkins Bloomberg School of Public Health

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

ARAPAHOE COMMUNITY COLLEGE PHYSICAL THERAPIST ASSISTANT PROGRAM 2018 Application for Admission

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY

Building Quality into Clinical Development: ASCEND-HF as a Case Example. Adrian Hernandez, MD and Craig Reist, PhD

SYNOPSIS. Publications No publications at the time of writing this report.

Transcription:

Revision of 06/14/2016 Page 1 of 7 CKD PILOT STUDIES Forms Completion Schedule - COMBINE Non-Patient Forms In order to make a clinical site ready to enroll F09 Clinical Center F10 Study Personnel Review items needed for start-up Consent visit n/a n/a Baseline Patient Forms Informed Consent (not entered into database. Includes Biorepository consent. Fax the de-identified signature page only to the DCC and write the PID and alphacode in the middle of the page.) Participant Information (See MOP this is not entered into database) Screening Visit (S0 visit) F107 Screening F115 Local Lab Serum and Plasma Screening Results F116 Local Lab Whole Blood Results F121 Local Lab Pregnancy Test Result 3 Visit At some time between Screening and B0 Visit -- Report Name Rpt Ready for Baseline (B0) Placebo Report Rpt Initial Baseline Bottle Number Assignment Report At some time between Screening and B1 Visit F122 Co-Morbidity and Medical History F123 Baseline Demographics, Employment, and Income MRI Forms At Anytime during Baseline F291 Cardiac and BOLD Renal MRI Submission (done for those who consented to MRI and was eligible for MRI based on the screening form) Run the Ready for Baseline (B0) Placebo Report. If the participant is eligible, proceed with B0.

Revision of 06/14/2016 Page 2 of 7 B0 Visit Rpt 3 F285 F148 B1 Visit 3 F149 F285 F300 F301 F329 F330 F331 F335 Baseline Placebo Bottle Assignment Visit GI Symptoms and Other AE s Baseline Initial Pill Dispensing Visit Baseline Pill Count GI Symptoms and Other AE s Biorepository Serum and Plasma Mailing Biorepository Urine Mailing FGF23 and R01 Sample Drawn and Stored FGF23 and R01 Sample Mailing (batched sample-shipped once each month) Spectra Lab Serum/Blood/Spot Urine Mailing Spectra Lab 24-Hr Urine Mailing Forms Completed by Central Labs (Spectra and UW FGF23Core) at B1 B2 Visit 3 F149 F285 F300 F301 F329 F330 F331 F335 Visit Baseline Pill Count GI Symptoms and Other AE s Biorepository Serum and Plasma Mailing Biorepository Urine Mailing FGF23 and R01 Sample Drawn and Stored FGF23 and R01 Sample Mailing (batched sample-shipped once each month) Spectra Lab Serum/Blood/Spot Urine Mailing Spectra Lab 24-Hr Urine Mailing Forms Completed by Central Labs (Spectra and UW FGF23Core) at B2 F361 Spectra Lab Whole Blood / HgbA1c Results Forms Completed by MRI Cores F701 Core Receipt of Cardiac MRI Form F702 Core Receipt of BOLD Renal MRI Form F711 Cardiac MRI Core Incidental Findings F712 BOLD Renal MRI Core Incidental Findings F721 Cardiac MRI Core Results F722 BOLD Renal MRI Core Results

Revision of 06/14/2016 Page 3 of 7 Reports can be run at anytime during Baseline Report Name Rpt Ready to Randomize Report Rpt On-Line Randomization Report As Needed during Baseline F163 Baseline (Pre-Randomization) Drop-out (includes drop-out for unanticipated pregnancy) F403 Re-Enrollment of a Previously Enrolled Participant F410 Late Consent for Biorepository F411 Withdrawal of Consent for Biorepository F511 Hospitalization Notification F512 Hospitalization Details F522 Details of SAEs that are Not Hospitalizations or Deaths F531 Death Notification F532 Detailed Death F540 Event Information Sent to the DCC F549 Vascular Access Created/Placed F550 Initiation of Chronic Dialysis or Transplant F551 Baseline/Follow-Up Pregnancy Reported Rpt Lanthanum Baseline Bottle Number Assignment (if baseline pills are lost) Rpt Nicotinamide Baseline Bottle Number Assignment (if baseline pills are lost) If the Ready to Randomize Report shows that participant is eligible for the study, proceed to the Randomization Screen to randomize the participant.

Revision of 06/14/2016 Page 4 of 7 Follow-up Patient Forms COMBINE Follow-up Visit: F0 (first post randomization visit) If FV0 is on same day or within 1 week of the B2 and there were no hospitalizations or other SAE, then only complete F248. If the FV0 is more than 1 week after the B2 visit and/or there was a hospitalization or other SAE, then complete the following forms: 3 Visit F248 Follow-up Initial Pill Dispensing Follow-up Visit: F1 3 Visit Form Form Completed by Central Labs (Spectra and UW FGF23Core) at F1 Follow-up Visit: F2 3 Visit Form Completed by Central Labs (Spectra and UW FGF23Core) at F2 Follow-up Visit: F3 3 Visit F300 Biorepository Serum and Plasma Mailing F301 Biorepository Urine Mailing F335 Spectra Lab 24-Hr Urine Mailing

Revision of 06/14/2016 Page 5 of 7 Forms Completed by Central Labs (Spectra and UW FGF23Core) at F3 Follow-up Visit: F6 Quarterly Urine Scale Calibration 3 Visit (completed at this visit only if new bottles are dispensed) F300 Biorepository Serum and Plasma Mailing F301 Biorepository Urine Mailing F335 Spectra Lab 24-Hr Urine Mailing Forms Completed by Central Labs (Spectra and UW FGF23Core) at F6 F361 Spectra Lab Whole Blood / HgbA1c Results Follow-up Visit: F9 3 Visit (completed at this visit only if new bottles are dispensed) Forms Completed by Central Labs (Spectra and UW FGF23Core) at F9 Follow-up Visit: F11 3 Visit (completed at this visit only if new bottles are dispensed)

Revision of 06/14/2016 Page 6 of 7 Follow-up Visit: F12 3 Visit F289 Participant End of Study Questionnaire F291 Cardiac and BOLD Renal MRI Submission (done for those who consented to MRI and was eligible for MRI based on the screening form) F300 Biorepository Serum and Plasma Mailing F301 Biorepository Urine Mailing F335 Spectra Lab 24-Hr Urine Mailing F475 Study Closeout completed by PI Forms Completed by Central Labs (Spectra and UW FGF23Core) at F12 F361 Spectra Lab Whole Blood / HgbA1c Results Forms Completed by Central MRI Cores F701 Core Receipt of Cardiac MRI Form F702 Core Receipt of BOLD Renal MRI Form F711 Cardiac MRI Core Incidental Findings F712 BOLD Renal MRI Core Incidental Findings F721 Cardiac MRI Core Results F722 BOLD Renal MRI Core Results As Needed during Follow-Up F250 Between Visit Phone Medication Change F286 Symptoms/Adverse Events Reported on Phone Calls or at Extra Non-Protocol Visits F380 Local Lab Adverse Event Recheck Results F410 Late Consent for Biorepository F411 Withdrawal of Consent for Biorepository F511 Hospitalization Notification F512 Hospitalization Details F522 Details of SAEs that are Not Hospitalizations or Deaths F531 Death Notification F532 Detailed Death F540 Event Information Sent to the DCC F549 Vascular Access Created/Placed Form F550 Initiation of Chronic Dialysis or Transplant F551 Post-Screening Pregnancy Reported

Revision of 06/14/2016 Page 7 of 7 F582 Study Medication Discontinuation Recommended by Lab Values F583 Reaction to Furosemide F593 Request for/report Unblinding Forms Completed by UW FGF23Core F364 UW Core Lab Serum FGF23 Results F365 UW Core Lab Special Lab Results Completed by CKD Event Review Committee F612 Event Review Committee Hospitalizations Review F622 Event Review Committee SAE s that are not hospitalizations or Death Review F632 Event Review Committee Death Review F663 Review Study Medication Unblinding